---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-044792"
form_type: "8-K"
ticker: null
cik: "0001442836"
company_name: "Mersana Therapeutics, Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T11:26:10.318369+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Mersana cuts workforce ~55%, eliminates internal pipeline, extends cash runway to mid-2026

## Summary
- Workforce reduction of approx. 55% across functions; substantially complete by Q3 2025.
- Company eliminates internal pipeline development; focuses Emi-Le (B7-H4 ADC) on breast cancer.
- Estimated restructuring costs of $4-5M for severance, benefits, and outplacement.
- Cash runway extended to mid-2026 through cost-saving initiatives.
- Conference call on May 15 to discuss business updates and Q1 2025 financial results.

## SEC filing metadata
- accession: 0001104659-25-044792
- form_type: 8-K
- cik: 0001442836
- company_name: Mersana Therapeutics, Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.05, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1442836/000110465925044792/0001104659-25-044792-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1442836/000110465925044792/tm2514089d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-044792
- JSON: https://secwatch.observer/filing/0001104659-25-044792.json
- Plain text: https://secwatch.observer/filing/0001104659-25-044792.txt

## Key facts
- Restructurings & Charges
  Mersana Therapeutics, Inc. announced a restructuring with charges of Restructuring costs of approximately $4-5 million in cash expenditures for severance, benefit payments, outplacement services and related expenses. affecting all functions (approximately 55% reduction of current employee base).
  - Type: restructuring
  - Charge: Restructuring costs of approximately $4-5 million in cash expenditures for severance, benefit payments, outplacement services and related expenses.
  - Affected area: all functions
  - Headcount: approximately 55% reduction of current employee base
  source text: On May 6, 2025, Mersana Therapeutics, Inc. (the “Company”) announced the implementation of a strategic restructuring and reprioritization plan. In connection therewith, on May 5, 2025, the Company’s board of directors approved certain expense reduction measures, including the Company’s commitment to a reduction of approximately 55% of the Company’s current employee base across all functions (the “Restructuring”). The Restructuring is expected to be substantially complete by the end of the third quarter of 2025. As a result of the Restructuring, the Company estimates that it will incur approximately $4-5 million in costs resulting from cash expenditures consisting of severance and benefit payments, outplacement services and related expenses.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1442836/000110465925044792/0001104659-25-044792-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.